HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC combination product active ingredients listing on display panel to be studied by FDA.

This article was originally published in The Rose Sheet

Executive Summary

OTC COMBINATION PRODUCT ACTIVE INGREDIENTS LISTING ON LABEL PDP TO BE EVALUATED in a labeling consumer com-prehension study planned by FDA. The purpose of the study, which addresses the "statement of identity" on labels, "is to investigate consumers' perceptions, processing and evaluation of the placement of active ingredient information on the front and/or back portion of the product package," FDA said in an Aug. 6 "supporting statement" on the research.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel